① CNOOC's net profit in the first quarter was nearly 40 billion yuan. What is the growth rate of production scale? ② Times Electric's revenue increased by about 30% in the first 3 months. What are the highlights of profit?
The important announcements for Hong Kong stocks yesterday are as follows:
1) Company news
$CNOOC (00883.HK)$: First quarter revenue of 111,468 billion yuan, up 14.1% year on year; net profit of 39.719 billion yuan, up 23.7% year on year.
In the first quarter, the company achieved a total net output of 180 million barrels of oil equivalent, an increase of 9.9% over the previous year. Mainly due to production contributions from the commissioning of new projects; and increased production in Guyana and Canada.
$CHALCO (02600.HK)$: Revenue for the first quarter was about 48.956 billion yuan, down 26.14% year on year; net profit was about 2.23 billion yuan, up 23.01% year on year.
$ZTE (00763.HK)$: Revenue for the first quarter was about 30.578 billion yuan, up 4.93% year on year; net profit was 2,741 billion yuan, up 3.74% year on year.
$SINOPEC SSC (01033.HK)$: Revenue for the first quarter was about 18.533 billion yuan, up 3.3% year on year; net profit was about 177 million yuan, up 22.1% year on year.
$CHINA OILFIELD (02883.HK)$: First quarter revenue of 10.148 billion yuan, up 20% year on year; net profit of 635.5 million yuan, up 57.3% year on year.
$CHINA LONGYUAN (00916.HK)$: Revenue for the first quarter was 9.877 billion yuan, up 0.10% from the same period last year; net profit was 2,482 billion yuan, up 2.59% year on year.
$TIMES ELECTRIC (03898.HK)$: Revenue for the first quarter was $3,925 million, up 27.2% year on year; net profit was 568 million yuan, up 30.44% year on year.
$SHANDONG XINHUA (00719.HK)$: Revenue for the first quarter was 2,475 billion yuan, down 6.25% year on year; net profit was 142 million yuan, down 6.41% year on year.
$YUE YUEN IND (00551.HK)$: Net profit for the first quarter is expected to increase by about 95% to 100% year-on-year. It has mainly benefited from the gradual recovery of the global footwear industry and the normalization of orders, which have led to improvements in capacity utilization and production efficiency, as well as support from the low base period effect.
$TIGERMED (03347.HK)$: Revenue for the first quarter was 1.66 billion yuan, down 8.00% year on year; net profit was 235 million yuan, down 58.65% year on year.
$CHINA SUNTIEN (00956.HK)$: Revenue for the first quarter was about 7.907 billion yuan, up 20.55% year on year; net profit was about 832 million yuan, down 0.89% year on year. The main reason is that the number of hours that can be used by the Group's wind farms decreased compared to the same period last year.
In addition, in the first quarter, the company completed 4.117,300 megawatt-hours of power generation, an increase of 0.27% over the previous year; the average feed-in tariff (excluding tax) was 0.43 yuan/kilowatt-hour, a year-on-year decrease of 2.48%.
$ASYMCHEM (06821.HK)$: Revenue for the first quarter was about 1.4 billion yuan, down 37.76% year on year; net profit was 282 million yuan, down 55.27% year on year.
$ZHEJIANG SHIBAO (01057.HK)$: Revenue for the first quarter was 493 million yuan, up 43.03% year on year; net profit was 21.7793 million yuan, up 140.12% year on year.
$QYUNS-B (02509.HK)$,$HANSOH PHARMA (03692.HK)$: The two sides have signed an exclusive external licensing agreement for R&D, production and commercialization of the monoclonal antibody inhibitor Qx004n targeting IL-23p19 in Greater China.
As the licensee, Hanson (Shanghai) Health Technology Co., Ltd., a subsidiary of Hanson Pharmaceuticals, will be responsible for the R&D, production and commercialization of all developable dosage forms and indications of QX004N in China, and will pay a down payment of RMB 75 million and potential payments for R&D, supervision and commercialization milestones of no more than RMB 1,032 million, as well as tiered royalties based on future product sales.
According to reports, QX004N is an innovative drug candidate for psoriasis and Crohn's disease. As of the date of publication of this announcement, QX004N has initiated a number of clinical studies. The highest stage of development in China is a phase II clinical trial.
$CH DISPLAY OPT (00334.HK)$: During the period, the Group's tablet module sales increased 22.6 times to 7,350 units, and total sales reached 10.85 million units, an increase of 9.0% over the previous year. The average sales price of overall products sold increased by 52.9% year on year to 93.8 yuan, and total turnover reached 932 million yuan, an increase of 57.3% year on year.
$BAY AREA DEV (00737.HK)$: In March, the total monthly toll revenue for the Guangzhou-Shenzhen Expressway and Guangzhou-Zhuxi Expressway was about 270 million yuan and 116.5 million yuan respectively, which was basically the same as the previous year. The total monthly toll revenue of the Yanjiang Expressway (Shenzhen section) was 58.191,000 yuan, an increase of 4% over the previous year.
3) Repurchase news
$CGN NEW ENERGY (01811.HK)$: It is proposed to use up to HK$157 million to repurchase no more than 64.3624 million shares of the company.
$HANG SENG BANK (00011.HK)$An announcement was issued to repurchase 600,000 shares at HK$61.109 million, at a repurchase price of HK$100.10-102.30.
$SWIRE PACIFIC A (00019.HK)$: Approximately HK$13.684,400 were spent to repurchase 216,000 shares at a repurchase price of HK$62.65 to 63.85.
$SIMCERE PHARMA (02096.HK)$: A repurchase of 1,816 million shares was spent at HK$9.503 million, at a repurchase price of HK$5.21-5.26.
Editor/Somer